Prime Medicine (PRME) Return on Capital Employed (2022 - 2026)
Prime Medicine posted quarterly Return on Capital Employed of 73.15% for Q1 2026, up 99.0% year-on-year from 36.76% in Q1 2025, and down 14.61% on a QoQ basis from 63.83% in Q4 2025.
Prime Medicine (PRME) has 5 years of Return on Capital Employed data on file, last reported at 73.15% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 99.0% year-over-year to 73.15%; the trailing twelve-month figure through Mar 2026 stood at 73.15% (up 99.0% YoY), and the FY2025 full-year result was 73.71%, up 2376.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 73.15%, down from 63.83% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 43.42% in Q1 2023 and bottomed at 127.94% in Q4 2023.
- The 5-year median for Return on Capital Employed is 73.65% (2025), against an average of 74.79%.
- The widest annual swing landed in 2023, when Return on Capital Employed slumped 8330 bps; it then jumped 5489 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 44.64% in 2022, then slumped by 187 bps to 127.94% in 2023, then surged by 43 bps to 73.04% in 2024, then gained by 13 bps to 63.83% in 2025, then declined by 15 bps to 73.15% in 2026.
- The last three Return on Capital Employed figures came in at 73.15% (Q1 2026), 63.83% (Q4 2025), and 68.68% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | -73.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.15% |
| Dec 31, 2025 | -63.83% |
| Sep 30, 2025 | -68.68% |
| Jun 30, 2025 | -75.78% |
| Mar 31, 2025 | -74.14% |
| Dec 31, 2024 | -73.04% |
| Sep 30, 2024 | -87.58% |
| Jun 30, 2024 | -84.41% |
| Mar 31, 2024 | -93.39% |
| Dec 31, 2023 | -127.94% |
| Sep 30, 2023 | -79.51% |
| Jun 30, 2023 | -57.60% |
| Mar 31, 2023 | -43.42% |
| Dec 31, 2022 | -44.64% |